Characterization of LY3324954 a long-acting glucagon-receptor agonist

Characterization of LY3324954 a long-acting glucagon-receptor agonist

Objective: Glucagon is a crucial regulator of glucose and lipid metabolism as well as whole-body energy balance. Thus, modulation of glucagon receptor (GCGR) activity in the context of single-molecule multi-receptor co-agonists has become an emerging therapeutic target against obesity and obesity-as...

Full description

Saved in:

Bibliographic Details
Main Authors:	William Roell, Tamer Coskun, Teayoun Kim, Libbey O’Farrell, Jennifer A. Martin, Shelly Nason, Jasmin Hernandez-Alamillo, Saidharshana Dhantu, Daniel J. Drucker, Kyle W. Sloop, James P. Steele, Jorge Alsina-Fernandez, Kirk M. Habegger
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Molecular Metabolism
Subjects:	Glucagon Insulin secretion Glucose homeostasis Diabetes Obesity
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212877824002047
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Different post-pancreatectomy glucagon responses to a meal test between surgical approaches
by: Tsuguka Matsuda, et al.
Published: (2023-11-01)

Autophagy-lysosome pathway in insulin & glucagon homeostasis
by: Yi Wu, et al.
Published: (2025-02-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)

Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity
by: Hao Hua, et al.
Published: (2025-01-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Glucagon, rather than Glucagon-Like Peptide 1, Mediates Higher Post-Lunch Glucose Excursions during Breakfast Skipping in Asian Indian Patients with Uncontrolled Type 2 Diabetes Mellitus
by: Yash V. Chauhan, et al.
Published: (2024-12-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

β-glucan attenuates intestinal ischemia-reperfusion injury in mice by promoting glucagon-like peptide-1 secretion
by: WANG Wei, et al.
Published: (2025-01-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
by: Aaron King, et al.
Published: (2025-03-01)

Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus
by: Mijin Kim, et al.
Published: (2025-01-01)

Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists
by: Xiaolei Miao, et al.
Published: (2025-01-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

The Physiological Role of GABA in Fine-Tuning Control of Blood Glucose and Diabetes Treatment
by: Mohsen Davari, et al.
Published: (2024-12-01)

G Protein-Coupled Receptor 17 Inhibits Glucagon-like Peptide-1 Secretion via a Gi/o-Dependent Mechanism in Enteroendocrine Cells
by: Jason M. Conley, et al.
Published: (2024-12-01)

Effects and mechanisms of long-acting glucagon-like peptide-1 receptor agonist semaglutide on microglia phenotypic transformation and neuroinflammation after cerebral ischemia/reperfusion in rats
by: Rulin Mi, et al.
Published: (2024-12-01)

The protective role of GLP-1 in neuro-ophthalmology
by: Sohum Sheth, et al.
Published: (2023-08-01)

Are obese rats influenced by GLP1 and IR through aerobic exercise? A case study
by: Ali Sayyah, et al.
Published: (2016-08-01)

Foundational contributions of Svetlana Mojsov to the GLP-1 field
by: George Barany, et al.
Published: (2024-10-01)

Detection of Insulin in Insulin-Deficient Islets of Patients with Type 1 Diabetes
by: Yuliya Krivova, et al.
Published: (2025-01-01)

Metabolic rate and insulin-independent glucose uptake increase in a TDP-43Q331K mouse model of amyotrophic lateral sclerosis
by: Tanya S. McDonald, et al.
Published: (2025-02-01)

Lethal Yellowing (LY) of Palm
by: Nigel A. Harrison, et al.
Published: (2019-05-01)

Lethal Yellowing (LY) of Palm
by: Nigel A. Harrison, et al.
Published: (2019-05-01)

Design, Structure–Activity Relationships, and Computational Modeling Studies of a Series of α-Helix Biased, Ultra-Short Glucagon-like Peptide-1 Receptor Agonists
by: Jonathon R. Sawyer, et al.
Published: (2024-12-01)

MSCs Contribute to the Conversion of Ly6Chigh Monocytes into Ly6Clow Subsets under AMI
by: Wenbin Lu, et al.
Published: (2020-01-01)

Intestinal butyric acid-mediated disruption of gut hormone secretion and lipid metabolism in vasopressin receptor-deficient mice
by: Kazuki Harada, et al.
Published: (2025-01-01)

A Stitch in Time
by: Brigid O’Farrell
Published: (2006-03-01)

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
by: Sho Furusawa, et al.
Published: (2024-06-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01)

Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis
by: Anna Skowronek, et al.
Published: (2025-01-01)

GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks
by: Ioannis Ilias, et al.
Published: (2025-01-01)

Clinical and morphological features of gastroduodenal pathology at alcohol-induced liver disease
by: I. V. Kozlova, et al.
Published: (2010-11-01)

Modulation of stress-related behaviour by preproglucagon neurons and hypothalamic projections to the nucleus of the solitary tract
by: Marie K. Holt, et al.
Published: (2025-01-01)

A Sense of Time(ly) Seeing in DeLillo’s Later Novels
by: Stefania Iliescu
Published: (2023-11-01)

Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies
by: Michelle Wei, et al.
Published: (2025-01-01)

From Clinical Trial Evidence to Clinical Guidelines: Perspectives on REWIND from Clinicians in the Gulf and Levant Region
by: Talal Ashour, et al.
Published: (2023-11-01)

Salivary Hormones Leptin, Ghrelin, Glucagon, and Glucagon-Like Peptide 1 and Their Relation to Sweet Taste Perception in Diabetic Patients
by: Nada K. Al-Ghurayr, et al.
Published: (2023-01-01)